OmniAb (OABI) investor relations material

Business overview and technology platform

• Licenses proprietary antibody discovery technology to over 110 active partners, including 8 of the top 10 global pharma companies.

• Technology platform features transgenic animals, AI-powered discovery, and novel scaffolds for antibody generation.

• Over 425 active programs, with 32 in clinical stages or approved, and 98% of programs have downstream economics.

• Recent launches of xPloration and OmniUltra expand growth opportunities and address critical challenges in antibody discovery.

• Business model includes upfront fees, collaboration revenue, milestones, and royalties on commercial sales.

Financial performance and guidance

• Q2 2026 total revenue reached $13.4M, up from $3.9M in Q2 2025; YTD revenue at $27.8M.

• Net loss for Q2 2026 was $5.9M, a significant improvement from $15.9M in Q2 2025.

• Cash costs and operating expenses (non-GAAP) for Q2 2026 were $13.3M; YTD at $25.5M.

• 2026 guidance: total revenue $32–36M, costs and operating expenses $84–88M, cash costs $51–55M, year-end cash $37–41M.

• Effective tax rate for 2026 expected to be ~0% due to a valuation allowance.

Partner pipeline and clinical progress

• 34 active clinical programs and approved products as of June 2026, with four new clinical additions in 2026.

• Multiple programs advancing to later clinical stages, including IMVT-1402, TEV-408, and precemtabart tocentecan.

• IMVT-1402 showed strong efficacy in difficult-to-treat rheumatoid arthritis; further data expected in 2026–2028.

• TEV-408 advancing to Phase 2b for vitiligo; precemtabart tocentecan moved directly to Phase 3 for metastatic colorectal cancer.

• Upcoming regulatory and clinical milestones include market approval for SAL003 in China and multiple data readouts in H2 2026.